Institute Seminar - Wednesday May 9th Tor Erik Rusten

Ghiasvand R (2026)
High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
Br J Dermatol (in press)
DOI 10.1093/bjd/ljaf523, PubMed 41483011

Unal B, Saatcioglu F (2025)
Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression
Biomark Res, 13 (1), 156
DOI 10.1186/s40364-025-00813-y, PubMed 41372991

Pinto R, Sjurgard IV, Pharo H, Mala T, Vedeld HM, Lind GE (2025)
Molecular stratification of esophageal adenocarcinoma: implications for prognosis and treatment strategy
Oncogene (in press)
DOI 10.1038/s41388-025-03650-3, PubMed 41361079

Ghiasvand R (2026)
High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
Br J Dermatol (in press)
DOI 10.1093/bjd/ljaf523, PubMed 41483011

Kristiansen SK, Shubin K, Zubrienė A, Matulis D, Dernjani N, Juzenas P, Bruland ØS, Juzeniene A (2026)
Radiobiological investigations of a [²¹²Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models
Int J Radiat Biol, 1-11 (in press)
DOI 10.1080/09553002.2025.2595630, PubMed 41481374

Emaldi M, Rey-Iborra E, Alamillo-Maeso P, Pulido R, Nunes-Xavier CE (2026)
Analysis of the Functional Impact of Glycosylation on Immune Checkpoint Proteins
Methods Mol Biol, 2959, 55-72
DOI 10.1007/978-1-0716-4734-9_4, PubMed 41028258